History
Feb 2023
First publication in human study
Online publication on LiGalli’s First in Human oxybutynin MedRing study showing favorable vaginal absorption and pharmacokinetics.
Sep 2022
Appointment of Unilever veteran Marga Mathijssen as CEO of LiGalli
Read all about it in our press release.
Dec 2021
Development partner Demcon published an article on LiGalli in their internal Demcon Investment newsletter
You can read the article for more details.
Sept 2021
LiGalli receives the International Life Sciences Award 2021
You can read the article for more details.
Apr 2021
The basic MedRing patent is granted in China
Sept 2020
The MedRing Alpha 1.0 is ready
The first in-human trials will start shortly.
March 2020
The basic MedRing patent is granted
First in the EU, later also in the US.
Dec 2019
The Dutch Government awards LiGalli the MIT subsidy
We look forward to working with our new partner Gimix ('TwentyNext' per July 2022).
"Our company owes its name to the island group in Italy, with these Ligalli islands emphasizing women's empowerment, just like our company's products."
Willem de Laat
Founder and Board Member of LiGalli B.V.
Founder and Board Member of LiGalli B.V.
Get in touch
Office
Leiden Bio Science Park – BioPartner 1
Address
J.H. Oortweg 21
2333 CH Leiden
The Netherlands
Disclaimer policy